Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

  • European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine
  • Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems
  • Zessly is the third EC approval for a Sandoz biosimilar in 12 months …
/by

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

  • European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine
  • Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems
  • Zessly is the third EC approval for a Sandoz biosimilar in 12 months …
/by